The study did not demonstrate a consistent impact of Lumacaftor/Ivacaftor therapy on glucose tolerance or insulin secretion in CF patients homozygous for Phe508del. Treatment responses were highly variable. The authors emphasize the need for larger studies with extended follow-up to better assess the drug’s effects on endocrine pncreatic function and its potential role in preventing CFRD. The gene discussed is INS; the disease is cystic fibrosis-related diabetes.